Kolltan Pharmaceuticals, the New Haven, CT-based developer of cancer drugs, said today it has raised an additional $5 million as part of its Series A financing, bringing the total round to $40 million. Kolltan, a spinout from the Yale University lab of Joseph Schlessinger, announced its initial $35 million financing in January. Investors in the Series A financing include Purdue Pharma, HBM BioCapital, the Pritzker/Vlock family, and other private life sciences investors.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
